Stocks
Thermo Fisher Scientific Financial Statements (TMO) |
||||||||||
| Thermo Fisher Scientificsmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 25.02.2021 | 24.02.2022 | 31.12.2022 | 23.02.2023 | 22.02.2024 | 01.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 32 218 | 39 211 | 44 915 | 44 915 | 42 857 | 42 278 | |||
| Operating Income, bln rub | 7 794 | 10 028 | 8 393 | 8 393 | 6 859 | 7 330 | ||||
| EBITDA, bln rub | ? | 10 192 | 12 964 | 11 760 | 11 941 | 10 800 | 10 406 | |||
| Net profit, bln rub | ? | 6 375 | 7 725 | 6 950 | 6 950 | 5 995 | 6 367 | |||
| OCF, bln rub | ? | 8 289 | 9 543 | 9 154 | 9 154 | 8 406 | 8 252 | |||
| CAPEX, bln rub | ? | 1 474 | 2 523 | 2 243 | 2 243 | 1 479 | 1 522 | |||
| FCF, bln rub | ? | 6 815 | 7 020 | 6 911 | 6 911 | 6 927 | 8 026 | |||
| Dividend payout, bln rub | 337.0 | 395.0 | 455.0 | 455.0 | 523.0 | 598.0 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 5.29% | 5.11% | 6.55% | 6.55% | 8.72% | 9.39% | ||||
| OPEX, bln rub | 8 612 | 10 009 | 8 598 | 10 993 | 10 254 | 12 780 | ||||
| Cost of production, bln rub | 15 713 | 18 977 | 25 415 | 25 415 | 27 633 | 25 176 | ||||
| R&D, bln rub | 1 181 | 1 406 | 1 471 | 1 471 | 1 337 | 1 370 | ||||
| Interest expenses, bln rub | 553.0 | 536.0 | 726.0 | 726.0 | 1 375 | 1 420 | ||||
| Assets, bln rub | 69 052 | 95 123 | 97 290 | 97 154 | 98 726 | 100 364 | ||||
| Net Assets, bln rub | ? | 34 507 | 40 793 | 44 032 | 43 978 | 46 735 | 48 992 | |||
| Debt, bln rub | 21 735 | 34 870 | 34 488 | 34 488 | 34 917 | 35 313 | ||||
| Cash, bln rub | 10 325 | 4 477 | 8 524 | 8 524 | 8 077 | 6 645 | ||||
| Net debt, bln rub | 11 410 | 30 393 | 25 964 | 25 964 | 26 840 | 28 668 | ||||
| Ordinary share price, rub | 465.8 | 667.2 | 550.7 | 550.7 | 530.8 | 447.5 | ||||
| Number of ordinary shares, mln | 396.0 | 394.0 | 392.0 | 392.0 | 386.0 | 382.0 | ||||
| Market cap, bln rub | 184 449 | 262 893 | 215 870 | 215 870 | 204 885 | 170 945 | ||||
| EV, bln rub | ? | 195 859 | 293 286 | 241 834 | 241 834 | 231 725 | 199 613 | |||
| Book value, bln rub | -4 219 | -21 277 | -14 606 | -14 696 | -13 955 | -13 996 | ||||
| EPS, rub | ? | 16.1 | 19.6 | 17.7 | 17.7 | 15.5 | 16.7 | |||
| FCF/share, rub | 17.2 | 17.8 | 17.6 | 17.6 | 17.9 | 21.0 | ||||
| BV/share, rub | -10.7 | -54.0 | -37.3 | -37.5 | -36.2 | -36.6 | ||||
| EBITDA margin, % | ? | 31.6% | 33.1% | 26.2% | 26.6% | 25.2% | 24.6% | |||
| Net margin, % | ? | 19.8% | 19.7% | 15.5% | 15.5% | 14.0% | 15.1% | |||
| FCF yield, % | ? | 3.69% | 2.67% | 3.20% | 3.20% | 3.38% | 4.70% | |||
| ROE, % | ? | 18.5% | 18.9% | 15.8% | 15.8% | 12.8% | 13.0% | |||
| ROA, % | ? | 9.23% | 8.12% | 7.14% | 7.15% | 6.07% | 6.34% | |||
| P/E | ? | 28.9 | 34.0 | 31.1 | 31.1 | 34.2 | 26.8 | |||
| P/FCF | 27.1 | 37.4 | 31.2 | 31.2 | 29.6 | 21.3 | ||||
| P/S | ? | 5.73 | 6.70 | 4.81 | 4.81 | 4.78 | 4.04 | |||
| P/BV | ? | -43.7 | -12.4 | -14.8 | -14.7 | -14.7 | -12.2 | |||
| EV/EBITDA | ? | 19.2 | 22.6 | 20.6 | 20.3 | 21.5 | 19.2 | |||
| Debt/EBITDA | 1.12 | 2.34 | 2.21 | 2.17 | 2.49 | 2.75 | ||||
| R&D/CAPEX, % | 80.1% | 55.7% | 65.6% | 65.6% | 90.4% | 90.0% | ||||
| CAPEX/Revenue, % | 4.58% | 6.43% | 4.99% | 4.99% | 3.45% | 3.60% | ||||
| Thermo Fisher Scientific shareholders | ||||||||||
